



Resonance Health Ltd (ASX:RHT) Appendix 4C – 3rd Quarter Cash Flow Report

Resonance Health Limited today released its third quarter cash flow report for the period ending 31 March 2010.

Cash at 31 March 2010 was \$2,348,000. This represents a decrease of \$184,000 for the March 2010 quarter as compared to a decrease of \$300,000 for the December 2009 quarter and an increase of \$187,000 for the September 2009 quarter resulting in a year to date cash reduction of \$297,000.

Receipts from customers increased from \$402,000 to \$456,000 from the previous quarter.

Expenditure for the quarter is focussed on increased marketing of Ferriscan in key markets including the USA and Research and Development of new diagnostic tests. The Company launched its Cardiac T2* analysis service during the quarter and continued to focus on the development of an MRI test for the measurement of liver fibrosis. Research and development costs increased from \$123,000 to \$194,000 from the previous quarter.

For further information please contact:

Resonance Health

Liza Dunne Managing Director T: +61 8 9286 5300 E: lizad@ferriscan.com

Eva O'Malley Company Secretary T: +61 8 9286 5300 E: evao@ferriscan.com

Rule 4.7B

Appendix 4C

Quarterly report

for entities admitted

on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

|--|

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

31 March 2010

Consolidated statement of cash flows

Cash	flows related to operating activities	Current quarter \$A'000	Year to date \$A'000
04522	and the second to opening activities	******	***
1.1	Receipts from customers	456	1,552
	Other Receipts	-	-
1.2	Payments for (a) staff costs	(285)	(836)
	(b) advertising and marketing	(68)	(179)
	(c) research and development	(194)	(453)
	(d) leased assets	-	-
	(e) other working capital	(62)	(197)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	14	57
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes (paid)/received	-	_
1.7	Other Payments (a) consulting & professional services	(3)	(49)
	(b) statutory & compliance	(18)	(107)
	(c) travel	(13)	(40)
	``	` /	
	Net operating cash flows	(173)	(252)

⁺ See chapter 19 for defined terms.

		Current quarter	Year to date
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)	(173)	(252)
	Cash flows related to investing activities		
1.9	Payment for acquisition of:		
	(a) businesses (item 5) (b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(11)	(45)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	=
	(b) equity investments	-	-
	(c) intellectual property (d) physical non-current	-	-
	assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (Cash introduced on acquisition of controlled entity)	-	-
	Net investing cash flows	(11)	(45)
1.14	Total operating and investing cash flows	(184)	(297)
1.15 1.16 1.17 1.18 1.19	Cash flows related to financing activities Proceeds from issues of shares, options, etc. Proceeds from sale of forfeited shares Proceeds from borrowings Repayment of borrowings Dividends paid	-	
1.20	Other (costs of capital raising)	-	-
	Net financing cash flows	-	-
	Net increase (decrease) in cash held	(184)	(297)
1.21 1.22	Cash at beginning of quarter/year to date Exchange rate adjustments to item 1.20	2,532	2,645
1.23	Cash at end of quarter	2,348	2,348

⁺ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	122
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	\$37k – Directors fees \$85k – Consulting fees	
		erial effect on consolidated
	\$85k – Consulting fees n-cash financing and investing activities Details of financing and investing transactions which have had a mat	erial effect on consolidated
No.1 [\$85k – Consulting fees n-cash financing and investing activities Details of financing and investing transactions which have had a mat assets and liabilities but did not involve cash flows	

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

⁺ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	280	153
4.2	Deposits at call	360	679
4.3	Bank overdraft		
4.4	Other (provide details)		
	1 month term deposit3 month term deposit7 month term deposit (maturing July 2010)	708 - 1,000	700 1,000
	Total: cash at end of quarter (item 1.22)	2,348	2,532

Acquisitions and disposals of business entities

Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
N/A	N/A
	(Item 1.9(a)) N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Eva O'Malley Company Secretary

⁺ See chapter 19 for defined terms.